Recurrent Urethral Cancer Completed Phase 2 Trials for Doxorubicin (DB00997)

Also known as: Urethral cancer recurrent / Urethra cancer recurrent

IndicationStatusPhase
DBCOND0028817 (Recurrent Urethral Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00478361Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney FunctionTreatment